BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte (MXCT)MaxCyteEarnings

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will

Related news

MXCTMaxCyte2026-07-15 20:05 EST

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

KRYSKrystal Biotech2026-04-21 12:00 EST

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

OCGNOcugen2026-04-29 11:02 EST

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

KRYSKrystal Biotech2026-07-23 21:00 EST

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

SGMOSangamo Therapeutics, Inc.2026-05-14 20:01 EST

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

SANASana Biotechnology2026-05-11 20:05 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-05-11 11:30 EST

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

View all latest news

MaxCyte

Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instruments introduce molecules into cells at laboratory through commercial scale while preserving cell viability and function. Strategic...

Recent company news

MXCTMaxCyte2026-07-21 12:05 EST

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

MXCTMaxCyte2026-07-15 20:05 EST

MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

MXCTMaxCyte2026-06-23 13:00 EST

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-04-29 20:05 EST

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

Stock data

Close
1.11 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States